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Abstract
Background: Although genotypic resistance testing (GRT) is recommended to guide combination antiretroviral therapy
(cART), funding and/or facilities to perform GRT may not be available in low to middle income countries. Since treatment
history (TH) impacts response to subsequent therapy, we investigated a set of statistical learning models to optimise cART
in the absence of GRT information.
Methods and Findings: The EuResist database was used to extract 8-week and 24-week treatment change episodes (TCE)
with GRT and additional clinical, demographic and TH information. Random Forest (RF) classification was used to predict 8-
and 24-week success, defined as undetectable HIV-1 RNA, comparing nested models including (i) GRT+TH and (ii) TH
without GRT, using multiple cross-validation and area under the receiver operating characteristic curve (AUC). Virological
success was achieved in 68.2% and 68.0% of TCE at 8- and 24-weeks (n=2,831 and 2,579), respectively. RF (i) and (ii) showed
comparable performances, with an average (st.dev.) AUC 0.77 (0.031) vs. 0.757 (0.035) at 8-weeks, 0.834 (0.027) vs. 0.821
(0.025) at 24-weeks. Sensitivity analyses, carried out on a data subset that included antiretroviral regimens commonly used
in low to middle income countries, confirmed our findings. Training on subtype B and validation on non-B isolates resulted
in a decline of performance for models (i) and (ii).
Conclusions: Treatment history-based RF prediction models are comparable to GRT-based for classification of virological
outcome. These results may be relevant for therapy optimisation in areas where availability of GRT is limited. Further
investigations are required in order to account for different demographics, subtypes and different therapy switching
strategies.
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Introduction
Current HIV-1 guidelines recommend genotypic resistance testing
(GRT) both before starting antiretroviral therapy (ART) and at
treatment failure. However, appropriate funding and/or facilities to
perform GRT may not be available in low to middle income
countries (LMIC), leaving physicians with switching therapy based
solely on the patient’s clinical background. Coupled with virological
and immunological measurements, treatment history (TH) is one of
the most crucial factors to play a role in the response to a new
treatment regimen. In fact, current (2010) recommendations of the
International AIDS Society-USA Panel [1] state that treatment
history should be considered when designing a new regimen.
In LMIC there is still need for cheap viral load tests to identify
early viral failures and limit the emergence of resistance [2]. In the
past five years there has been an increase in HIV/AIDS
surveillance, but there is still a general lack of rational collection
and utilisation of the data as well as of appropriately trained
medical staff [3,4,5]. Specific approaches for ART management
have been designed by the World Health Organization [6]. Public
health programs leading to earlier HIV diagnosis and initiation of
ART are expected to improve patient outcomes in LMIC [7].
It has been shown that drug costs are a major factor impairing
optimal HIV-1 drug sequencing [8]. Access to second-line ART
regimens in LMIC is problematic, mainly because of the expense
of HIV protease inhibitors (PI) [9], and CD4 monitoring is often
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13753the sole surrogate marker available to guide the management of
the infection [10]. However, immunologic criteria to predict which
patients have not achieved virological suppression results in
significant misclassification of treatment responses [11]. Attempts
to model the virological efficacy of ART in LMIC have been
proposed by Colebunders et al. [12].
Given the need for low-cost viral load assays, evaluations of
alternative technologies have been carried out [13,14]. The costs
for genotype resistance testing (GRT) also remain prohibitively
high for most LMIC, with only a few facilities being able to
support the expenses, execute the tests and exploit the results [15].
New relatively cheap technologies for GRT and non-B subtypes
analysis have also been proposed [16], but these have not yet been
propagated sufficiently. An additional challenge is the genetic
diversity of HIV-1, since most infected patients in developing areas
harbour non-B subtypes that could respond to therapy differently
from subtype B, the clade which has been extensively treated in
Western countries [17,18].
The virological benefit of genotype-guided treatment decisions
has been convincingly demonstrated in the last decade [19,20,21].
Although investigated to a lesser extent, genotype-guided treatment
decisions were shown to be superior to those based on the medical
history[22]. Accordingly,there is a plethora of GRT-based decision
systems either for single drug susceptibility scoring or combined
ART (cART) optimisation, from rule-based [23,24,25] to machine
learning approaches [26,27,28,29,30,31,32]. On the other hand,
attempts to guide treatment decisions using the TH information
alone have been exploited only recently, using artificial neural
networks, with extremely promising results [33].
In this work we aimed at investigating a set of statistical learning
models – called random forests - for optimisation of antiretroviral
therapy in the absence of GRT information, using the treatment
history as a surrogate predictor. Furthermore, we compare the
performance of TH-based to those of GRT-based models.
Methods
Ethics statements
This study uses anonymous retrospective data from European
merged study cohorts and biological material was not employed in
any step of the analysis. All the single data providers had
previously obtained patients’ informed consent for the execution of
retrospective studies and their inclusion in merged cohorts,
accomplishing national and international ethical issues. The study
design was eventually approved by a global scientific committee
and by local scientific committees of each single data provider.
Study design
The EuResist retrospective database (http://www.euresist.org/)
was used to extract patients’ treatment change episodes (TCE),
previously introduced by the HIV Resistance Response Database
Initiative [31] and by the Forum for Collaborative HIV Research
[34], in the so-called form of standard datum (SD).
Each SD was defined as a patient’s new regimen (TCE), either a
first-line or a subsequent line of therapy, coupled with a follow-up
HIV-RNA measured at 8 weeks (ranging from 4 to 12) and at 24
weeks (ranging from 20 to 28) of unmodified therapy.
TCE included antiretroviral compounds approved by the Food
and Drug Administration and by the European Medicine Agency:
the nucleoside/nucleotide reverse transcriptase inhibitors (NRTI)
lamivudine, abacavir, zidovudine, stavudine, zalcitabine, didano-
sine, emtricitabine and tenofovir disoproxil fumarate; the non-
NRTIs (NNRTI) efavirenz, nevirapine and etravirine; the protease
inhibitors (PI) amprenavir/fosamprenavir, atazanavir, indinavir,
lopinavir, nelfnavir, full-dose ritonavir, boosting-dose ritonavir,
saquinavir, tipranavir and darunavir; the fusion inhibitor enfuvir-
tide. Each drug was represented by a binary variable encoding its
presence/absence in a TCE. No restrictions concerning the
number of drugs included in a regimen were applied. Both
suboptimal treatment regimens made of ,3 drugs or salvage
regimes with .4 drugs were included. It was previously shown
that the inclusion of suboptimal TCE can improve data-driven
model performance [31]. The number of drugs in the regimen was
considered as a numerical variable.
Each TCE was provided with a contemporary HIV-1 genotype
(spanning protease and reverse transcriptase genes) or the closest
within 90 days before the TCE start date. The viral genotype was
encoded as binary vector of mutations, insertions and deletions
with respect to the HIV-1 consensus B reference, and the viral
subtype was determined by a BLAST search on the latest subtype
reference set provided by the Los Alamos repository (http://www.
hiv.lanl.gov/).
The closest (e.g. baseline) HIV-RNA and CD4+/CD4% cell
count measurements previous to the TCE start date (obtained at
most 90 days before, provided that no other therapies were started
and stopped during this time window) were collected. Patient’s
demographic information was also retrieved, including age,
gender, mode of HIV transmission (drug user, heterosexual,
homosexual/bisexual, blood products, mother-to-child transmis-
sion), and country of origin.
We associated to each TCE the previous patient’s drug
exposures, codifying a binary variable for each compound if that
drug was experienced for more than 12 months. Three additional
binary variables were defined summarising the exposures to the
NRTI/NNRTI/PI classes, and a numerical variable representing
the regimen line (any drug change in a combination therapy for
any reason).
We defined a virological success at 8-weeks, as the achievement
of an undetectable HIV-RNA or a decrease of at least 2 Log10
from the baseline HIV-RNA. At 24-weeks, the virological success
was defined as the achievement of an undetectable viral load.
Because of the inclusion of many viral load data obtained with
non-ultrasensitive assays, a 500 cp/ml threshold was applied for
the definition of undetectable HIV-RNA.
Additional details for the study design, the SD definition and
data extraction procedures and constraints have been discussed
previously [30,31,34]. For simplicity, we will refer to the two
defined 8-week and 24-week SD sets, containing viral genotypic
information, as SD8G and SD24G, respectively. Of note, these
TCE correspond exactly to those used in [30], in order to
maintain a fair comparison with other tested methods, such as
expert rule bases. Indeed, the EuResist DB is periodically updated
from the local sources (currently Italy, Germany, Sweden, and
Luxembourg) participating to the network.
Two other data sets were extracted using the same notion of
SD, except for relaxing the need of a baseline GRT, and including
additional data from the Virolab study group (http://www.
virolab.org/), comprising the cohorts of Belgium (Katholieke
Universiteit Leuven) and Spain (fundacio ` irsiCaixa). These two
sets, containing treatment history but not mandatorily baseline
GRT, were named SD8H and SD24H, respectively.
Statistical methods
Random Forests (RF) were used to predict 8- and 24-week
outcomes and to assess variable importance [35]. RF are a non-
linear statistical learning methodology for classification and
regression. They ensemble several decision trees (usually from
hundreds to thousands) and give predictions by taking either the
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Specifically, each single tree is fully grown on a bootstrap sample
of the training data, without pruning the leaves, and at each node
split only a subset of the variables is considered. RF present many
advantages with respect to other non-linear machine learning
methods, such as neural networks, since they usually yield high
performance, are robust to over-fitting, can handle a large number
of variables, and provide a measure of variable importance.
In our study, the tree number and number of candidate
variables at each split of RF were optimised preliminarily with a
bootstrap approach. The area under the receiver operating
characteristic curve (AUC) [36] was adopted to evaluate the
model fit. The AUC is equal to the probability that a classifier will
rank a randomly chosen positive instance higher than a randomly
chosen negative one, whereas a receiver operating characteristic
(ROC) plot provides a graphical evaluation of true-positives
(sensitivity) versus false-positives (1-specificity) tradeoffs. Multiple
10-fold Cross Validation (CV) and Bengio’s corrected t-test
[37,38], controlling the false discovery rate with Benjamini-
Hochberg method, were used to compare model performance.
The following nested models were defined: (i) full set of input
covariates (including GRT and TH); (ii) full set of input covariates,
excluding GRT information, but keeping TH; (iii) full set of input
covariates, excluding TH, but keeping GRT; (iv) current cART,
baseline HIV-1 RNA and CD4; (v) current cART.
We also designed a set of sensitivity analyses as follows: in order
to investigate the potential bias derived from the fact that most of
the TCE present in the data base have been decided after a GRT,
we excluded from SD8H/SD24H all TCEs for which a baseline
GRT was available, and we compared models with/without
baseline HIV-RNA load as a covariate. From this reduced data
set, we selected first- and second-line regimens commonly
available in LMIC (TCE containing enfuvirtide, tipranavir,
darunavir, and etravirine were removed) and repeated model
evaluations. Finally, SD8G was split into two sets according to the
viral subtype of each associated GRT, grouping B and non-B
subtypes. RF models were trained on the subtype B dataset and
tested against the non-B.
The analyses were carried out using R, open-source software for
statistical computing [39], and Weka, a data-mining suite [40].
Results
Study population
From the EuResist data base, we collected 2,831 and 2,579
standard datum instances for the 8-week (SD8G) and 24-week
(SD24G) outcome, respectively. Virological success was reported
in 68.2% and 68.0% of cases, respectively. Suboptimal therapies
(dual- and mono-therapies), had a prevalence of 6.2% and 5.5% in
the 8-week and 24-week data set. The majority of cART contained
lamivudine (55.9%), any PI/r (42.7%, where lopinavir/r account-
ed for 36.2%), tenofovir (34.8%), zidovudine (31.7%), didanosine
(28.4%), stavudine (24.0%), efavirenz (17.5%), abacavir (16.0%),
and nevirapine (10.6%). Darunavir, tipranavir, etravirine, enfuvir-
tide, raltegravir, and maraviroc were not present in the data set.
Additional details on cART distribution are available in [30] or
can be provided by posting a request to the EuResist study group.
Relaxing the need for a baseline GRT, the data sets SD8H and
SD24H were extracted (n=12,932 for both outcome points).
Seventy-one percent of patients reached virological success at 8-
weeks and 67% of patients reached virological success at 24-weeks.
Differences in proportions of SD8H and SD24H with SD8G and
SD24G success rates yielded p,0.0001 and p=0.13, respectively.
The percentage of suboptimal therapies was 8%. The majority of
cART contained lamivudine (63%), zidovudine (33%), tenofovir
(28%), stavudine (27%), any PI/r (29%, where lopinavir/r
accounted for 23%), didanosine (21%), abacavir (19%), and
efavirenz (11%). There was a low percentage of darunavir (1.3%)
and tipranavir (1.3%) containing cART.
Table 1 summarises patients’ baseline characteristics both for
SD8G and SD8H.
Comparison between GRT-based and TH-based RF
models
Table 2 and Figure 1 show detailed performance results and
ROC plots for SD8G and SD24G, comparing RF models (i)
through (v), under multiple 10-fold CV. Model (i), which includes
the full set of covariates (including both GRT and TH), was the
best performing in terms of AUC for both time points. However,
model (ii) (TH but not GRT) had AUC distributions not
significantly different from model (i) at 8-weeks (p=0.25) although
inferior at 24-weeks (p=0.04). The same held for model (iii) (GRT
but not TH), which was comparable to (i) at 8-weeks (p=0.28) and
inferior at 24-weeks (p,0.0001). On the other hand, models (iv)
and (v) were always significantly outperformed by models (i) to (iii)
at any time point (all p,0.0001). Model (ii) and (iii) did not show
significant differences in AUC at both time outcomes (p=0.7 and
0.113).
We also compared AUC of models (i), (ii), and (v) by stratifying
for the therapy line (first-, second-, third-, fourth-line or more).
Detailed results are shown in Table 3. Interestingly, both model (i)
and (ii) show significantly better performance as compared to the
base cART model (v) only at late switches. Figure 2 (panel a)
depicts the AUC for each model and therapy strata over a single
10-fold CV run using the SD8G data set, and the proportion of
virological successes for each therapy line (panel b).
When executing CV on SD8H and SD24H, only RF models (ii),
(iv) and (v) were testable (since GRT information was not present).
Average (st.dev.) AUC values for model (ii) were 0.799 (0.011) at 8-
weeks, and 0.832 (0.009) at 24 weeks. Model (iv) had average
(st.dev.) AUC of 0.742 (0.012) at 8-weeks, and 0.752 (0.012) at 24
weeks. Model (v) had an average AUC of 0.684 (0.014) and 0.714
(0.013) at 8- and 24-weeks, respectively. Differences in AUC
between (ii) and (iv) were significant both at 8-weeks and at 24-
weeks (p,0.0001). As expected, the difference was even larger
between model (ii) and (v) (p,0.0001 both at 8- and 24-weeks).
Figure 3 depicts ROC curves both for SD8H and SD24H.
Sensitivity analyses
Since all the extracted data sets may be biased due to the fact
that in Europe the prevalence of genotype-guided TCE is high, we
excluded from SD8H and SD24H all the TCE for which there was
a baseline GRT available (obtaining n=9,623). This is meant to
be an approximation to the set of non-genotype-guided therapies,
although some baseline GRT may have been available but not
inserted in the data base. In a sub-analysis, then, we deleted the
HIV-RNA variable. The proportion of successes was 71% and
65% at 8- and 24-weeks, respectively. For the 8-weeks outcome,
average (st.dev.) AUC for models (ii), (iv), and (v) were 0.809
(0.015), 0.753 (0.015), and 0.685 (0.017). For the 24-weeks
outcome, average (st.dev.) AUC for model (ii), (iv), and (v) were
0.839 (0.013), 0.765 (0.014), and 0.709 (0.018). Model (ii)
significantly outperformed both models (iv) and (v) at all time
points (p,0.0001). When removing the HIV-RNA variable, for 8-
weeks outcome the average (st.dev.) AUC for models (ii) and (iv)
were 0.758 (0.015) and 0.654 (0.016), p,0.0001; for 24-weeks
outcome, the average (st.dev.) AUC for models (ii) and (iv) were
0.807 (0.015) and 0.670 (0.014), p,0.0001. Notably, model (ii)
Treat HIV without Genotyping
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HIV-RNA at 24-weeks (p,0.0001), but not at 8-weeks
(p=0.4387).
Models (ii), (iv) and (v) were also tested on SD8H and SD24H
excluding not only GRT-guided TCE, but also restricting to first-
(NRTI/NNRTI) and second-line (NRTI/NNRTI/PI) regimens
(n=3,640) available in LMIC. Percentage of virological successes
at 8- and 24-weeks were 79% and 75%. For the 8-weeks outcome,
model (ii) had an average (st.dev) AUC of 0.76 (0.03), significantly
higher (p,0.0001) than model (iv) and (v), that yielded AUC of
0.71 (0.03) and 0.70 (0.03), respectively. The same held for the 24-
weeks outcome, where model (ii) had an average (st.dev) AUC of
0.81 (0.02), significantly higher (p,0.0001) than model (iv) and (v),
with AUC of 0.75 (0.03) and 0.74 (0.03), respectively.
As a final evaluation, a special training/test data split was used
for SD8G. The split was based on the subtype of the virus.
Precisely, TCEs were grouped into subtype B or non-B, resulting
in n=2,353 and 478 instances, respectively. RF model (i) and (ii)
were trained and 10-fold cross-validated on the B subtype set, and
then tested against the non-B set. The proportion of successes at 8-
weeks was 67% for B and 73% for non-B subtypes. In a single 10-
fold CV run, model (i) yielded an average AUC of 0.765, model (ii)
of 0.757, and model (iii) of 0.753. On the test set (i.e. non-B
subtypes), AUC was 0.721 for model (i), 0.721 for model (ii), and
0.653 for model (iii).
AUC plots for the sensitivity analyses, along with variable
importance evaluation on the SD8H data set, are available as
supplementary material (Figure S1, Figure S2 and Material S1).
Discussion
Following the demonstration of a major role for HIV-1 drug
resistance mutations in response to antiretroviral therapy, GRT
has been the standard decision tool to face HIV-1 drug resistance
in clinical practice. The caregiver can use one or multiple systems
developed to translate HIV-1 genotype into clinically relevant
information. Commonly used genotype interpretation systems do
not integrate additional patient information as an input to
complement HIV-1 genotype in the effort to predict response to
cART. A few experimental systems derived from statistical
learning have recently been described which integrate patient
and virus information to build an effective antiretroviral regimen
[30,31,41]. These systems confirmed that TH has an impact on
prediction of response to therapy.
The expanding cART coverage of LMIC poses new challenges for
optimising treatment due to limited availability of second-line and
Table 1. Patients’ baseline characteristics.
Factor SD8G SD24G SD8H/SD24H
Average (SD) patient age years 42 (13) 42 (13) 46 (9) *
Male gender 70% 70% 72% *
Mode of HIV-1 transmission
Intravenous drug users 27% 27% 21% *
Homosexual men 32% 35% * 33% *
Heterosexual 38% 35% * 30% *
Nationality
European or North American 72% 73% 71%
Previous exposure to antiretroviral classes (.=1 year)
NRTI 74% 71% * 59% *
NNRTI 41% 40% 24% *
PI 58% 55% * 43% *
Median (IQR) number of previous treatment lines 3 (126) 3 (026) * 3 (127) *
Median (IQR) number of drugs included in the cART 3 (324) 3 (324) 3 (324) *
Laboratory markers
Median (IQR) HIV-1 RNA load Log10 cp/ml 4.4 (3.825.0) 4.4 (3.725.0) 4.0 (2.224.9) *
Median (IQR) CD4+ count cells/mm
3 255 (1372397) 276 (1522384) 285 (1602449) *
Subtype distribution
B 83% 85% * n/a
C 3% 3% n/a
02_AG 2.5% 2.2% n/a
F1 2.3% 1.7% n/a
Resistance mutations
Median (IQR) no. of IAS NRTI mutations 1 (023) 1 (023) n/a
Median (IQR) no. of IAS NNRTI mutations 0 (021) 0 (021) n/a
Median (IQR) no. of IAS PI mutations 3 (225) 3 (225) n/a
Summary of patients’ baseline characteristics for 8- and 24-weeks data sets with a baseline GRT available (SD8G, n=2,831; SD24G, n=2,579) and the data set without a
baseline GRT (SD8H and SD24H, n=9,623). Values with * highlight significant differences between SD8G and SD24G or between SD8G and SD8H (p,0.05, by t-test,
Wilcoxon rank sum or differences in proportion where appropriate).
doi:10.1371/journal.pone.0013753.t001
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GRT. Our analysis suggests that availability of basic patient data
supplemented with simplecategorical indicators of pasttreatment can
provide short- and medium-term response prediction as accurately as
in the presence of HIV-1 genotype information. This finding is not
surprising since the virus genotype is actually shaped by anti-HIV-1
compounds and can thus summarize the patient TH. It is interesting
to note that the performance of the GRT-based model, which didnot
include any information on TH, decreased, although not significant-
ly, at24-weeks,compared tothat ofTH-containing models.Thismay
be a consequence of the fact that bulk genotyping does not capture
minority variants that have been selected by previous exposures [42]
or resistant variants that survived in a reservoir and will be quickly
reselected. It should be worth evaluating whether using the
cumulative or historical genotype, made by the sum of all the
available genotypes, improves accuracy at a later time point [43,44].
Figure 1. ROC analysis of models’ performance. ROC plots of a single 10-fold CV run for RF models (i) through (v) for 8- and 24-weeks outcome
(SD8G and SD24G).
doi:10.1371/journal.pone.0013753.g001
Table 2. Model performance.
RF model input variable set 10610-fold CV AUC
8-weeks outcome (SD8G) 24-weeks outcome (SD24G)
average (st.dev.) average (st.dev.)
(i) GRT + TH + HIV RNA + CD4 + DEMOGRAPHIC + cART 0.77 (0.031) 0.834 (0.027)
(ii) TH + HIV RNA + CD4 + DEMOGRAPHIC + cART 0.757 (0.032) 0.821 (0.025)
(iii) GRT + HIV RNA + CD4 + DEMOGRAPHIC + cART 0.762 (0.035) 0.807 (0.025)
(iv) cART + HIV RNA +CD4 0.699 (0.037) 0.72 (0.03)
(v) cART 0.65 (0.041) 0.687 (0.03)
Summary of area under the receiving operating characteristic curve (AUC) values for RF trained with selected input variable sets, calculated over ten multiple runs of
10-fold cross-validation (8-weeks and 24-weeks outcome).
GRT = genotype resistance test.
TH = treatment history.
cART = combination antiretroviral therapy.
doi:10.1371/journal.pone.0013753.t002
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high-sensitivity genotype data [45] possibly resulting in better
prediction of response to therapy. We also found that both the RF
modelswithGRT+TH and the TH alone increase their performance
in predicting the virological outcomes when considering subsequent
therapy lines. This suggests that the outcomes of the first/second lines
a r es o m e h o wl e s sd e p e n d e n to nt h ev i r a ls t r a i no ro nt h ee a r l yA R T
exposures, while the evaluation of TH and the execution of a GRT
boost up the confidence in predicting the correct outcome at later
ART stages. In principle, continuous measures of exposure to
therapy, i.e. corrections based on duration and last time of use, could
improve the power of TH as a covariate. However, such detailed
information is often hard to obtain, particularly in the absence of
centralised (electronic) medical records. The simplicity of the input
information should expedite further training of TH-based systems
with data derived from these areas. In this context, the data required
forqueryingaTH-basedexpertsystemshouldbekeptsimpleinorder
to encourage its use. The input dataset investigated in this work was
made of demographic data typically available at any HIV clinic
(patient age, gender and route of infection), baseline markers (CD4
cell count and HIV-RNA load), just coupled with binary indicators
for past use of individual drugs (and derivatively of drug classes).
We showed that when the HIV-RNA covariate is deleted the
AUC performance decrease, which is an argument in favour of the
use of viral load monitoring for the optimization of cART in
LMIC. This reconciles with another recent study from Revell et al.
[33], that explored either artificial neural networks or RF for the
prediction of virological outcomes in absence of GRT information,
using data from Europe, North America, Japan and Australia
(.3,000 TCE). Revell et al. showed that, besides the GRT, the
Figure 2. Models’ performance evaluation by therapy line. Plot (panel A) of AUC of 10-fold CV for models (i), (ii) and (iv) by stratifying for
therapy line (SD8G). Performance decrease significantly by decreasing the number of drug switches, and the loss in AUC is as pronounced in TH-
based as in the other models. The proportion of virological successes (panel B) decreases significantly by increasing the therapy line (p,0.0001).
doi:10.1371/journal.pone.0013753.g002
Table 3. Model performance by therapy line.
RF model input variable set 10610 fold average AUC (st.dev.)












n=653 n=337 n=299 n=1542 n=671 n=314 n=254 n=1340
(i) GRT + TH + HIV RNA + CD4
+ DEMOGRAPHIC + cART
0.56 (0.09) 0.60 (0.11) 0.71 (0.11) 0.78 (0.04) 0.61 (0.17) 0.64 (0.12) 0.68 (0.12) 0.80 (0.03)
(ii) TH + HIV RNA + CD4 +
DEMOGRAPHIC + cART
0.62 (0.10) 0.62 (0.11) 0.66 (0.11) 0.75 (0.03) * 0.59 (0.16) 0.63 (0.12) 0.68 (0.11) 0.79 (0.04)
(v) cART 0.58 (0.11) 0.53 (0.10) 0.58 (0.11)* 0.62 (0.05) * 0.55 (0.17) 0.64 (0.09) 0.60 (0.12) 0.61 (0.05) *
Summary of area under the receiving operating characteristic curve (AUC) values for RF trained with selected input variable sets, calculated over ten multiple runs of
10-fold cross-validation (8-weeks and 24-weeks outcome), by stratifying for therapy line.
*p,0.05 with respect to the best model.
GRT = genotype resistance test.
TH = treatment history.
cART = combination antiretroviral therapy.
doi:10.1371/journal.pone.0013753.t003
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the accuracy of the prediction of virological outcomes.
In a sub-analysis, we showed that the accuracy of the prediction
models decreased when training on HIV-1 subtype B data and
validating on non-B subtype data. While non-B grouping is an artificial
approach not corresponding to any biological entity, differences in
response to certain cART regimens with specific subtypes may occur
and must be considered in the development of treatment decision tools.
A limitation of our study is that the datasets used do not
correspond to a typical scenario of LMIC, since models were
applied on data composed by patients cared in Europe. However,
we performed sensitivity analyses excluding GRT-guided TCE,
and including only first- and second-line regimens with drugs
available in LMIC. But a more detailed investigation is advisable
since the outcome distributions varied significantly across different
datasets. Although the compounds considered in these analyses
can be accessible in LMIC, drug combinations might differ.
In addition, in LMIC additional factors like co-morbidity with
other diseases, cost of treatment, distance to treatment centres,
interruptions of stocks for drugs during certain periods, and stigma
can play an important role in treatment outcome. This
information needs to be integrated in a system specifically
designed for LMIC, provided that co-operation efforts for data
collection are appropriately set up.
Another critical point is the fact that therapy switches in
EuResist are mainly driven by virological monitoring, and not by
clinical/immunological criteria, that are commonly used in LMIC.
Finally, in this study a 500-copy threshold in the definition of
undetectable viral load was used. This was due to the inclusion of
HIV-1 RNA data derived from old generation laboratory assays:
although this is a strong limitation for a model designed for high-
income countries, where the virological reduction below 50 cp/ml
would be the necessary outcome, in LMIC the end-point might be
revised by considering the HIV-RNA only where testing is
available and CD4/clinical monitoring otherwise.
Despite these limitations, prediction of response to treatment
based on TH rather than on GRT appears to be an appealing
strategy providing a possibility to help clinicians with data-driven
systems in the absence of HIV-1 genotype information. We realize
that the here described model is only applicable when therapy
failures are mainly judged from viral load monitoring, and when
further lines of treatment are available, which is currently not the
case in LMIC. However, the concept of the model warrants
optimism towards the development of more appropriate models for
LMIC. Thus, further development along these line are warranted,
along with a coordinated effort to collect HIV-1 treatment related
data from the areas that could maximally benefit from it.
Supporting Information
Material S1
Found at: doi:10.1371/journal.pone.0013753.s001 (0.03 MB
DOC)
Figure S1 Variable importance evaluation by RF model (ii) on
SD8H: mean decrease in Gini index.
Found at: doi:10.1371/journal.pone.0013753.s002 (0.17 MB TIF)
Figure 3. ROC analysis of GRT-free model performance. ROC plot of a single 10-fold CV run for RF models (ii) vs. (iv) vs. (v) for 8- and 24-weeks
outcome (SD8H and SD24H).
doi:10.1371/journal.pone.0013753.g003
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load as a covariate.
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